Illumina prepared to divest GRAIL if FTC appeal fails
Sundry Photography/iStock Editorial via Getty Images


Illumina (NASDAQ:ILMN) said that if an appeal of an FTC order that it divest GRAIL fails, it will follow the order and let go of the company it acquired in 2021.
Illumina (ILMN) said it will request an expedited review.

Illumina (ILMN) said it is hoping that a decision will be rendered by the US Court of Appeals by late 2023 or early 2024. This is around the same time that a decision is expected from the European Court of Justice on an appeal from the company. European regulators declined to approve the acquisition, but Illumina (ILMN) proceeded with it anyway.
"Winning both appeals would maximize value for shareholders," Illumina (ILMN) said in a news release. "It enables Illumina (ILMN) to expand the availability, affordability and profitability of the groundbreaking Galleri test in the $44-plus billion multi-cancer screening market."
Read why Seeking Alpha contributor The Value Investor recently issued a hold rating for Illumina (ILMN).